Author's response to reviews

Title: Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors

Authors:

Florence Brellier (florence_brellier@hotmail.com)
Enrico Martina (enrico.martina@fmi.ch)
Martin Degen (MDEGEN@PARTNERS.ORG)
Nathalie Heuzé-Vourc’h (nathalie.vourch@univ-tours.fr)
Agnès Petit (agnes.petit@univ-tours.fr)
Thomas Kryza (thomas.Kryza@univ-tours.fr)
Yves Courty (courty@univ-tours.fr)
Luigi Terracciano (lterracciano@uhbs.ch)
Christian Ruiz (christian.ruiz@unibas.ch)
Ruth Chiquet-Ehrismann (ruth.chiquet@fmi.ch)

Version: 4 Date: 12 April 2012

Author's response to reviews: see over
April 12, 2012

Dear Editor,

We were suggested to transfer our manuscript from Molecular Cancer to BMC Cancer and would like to submit our work entitled “Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors” by Brellier et al. for publication.

Tenascins are a family of large extracellular matrix glycoproteins associated with cell motility, proliferation and differentiation. The best described member is tenascin-C, which is highly expressed in cancer stroma where it contributes to the metastatic behavior of tumors.

Tenascin-W is the most recently discovered and the least studied member of the tenascin family. Here we found that tenascin-W is an even better tumor marker than tenascin-C in melanomas as well as pancreas, kidney, and lung carcinomas. Furthermore, its expression in the vicinity of blood vessels makes it a good candidate for a cancer biomarker of broad potential for tumor targeting approaches.

I hope that you find these data interesting enough to consider publication in your journal BMC Cancer.

With my best regards,

Ruth Chiquet-Ehrisman